ClinicalTrials.gg
RecruitingNCT06349811Updated Nov 2, 2026

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of BL-M05D1 in Locally Advanced or Metastatic Solid Tumors, sponsored by Biokin (Shanghai) Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors.

02

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Biokin (Shanghai) Biopharmaceutical Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form and comply with protocol requirements;
  2. No gender restriction;
  3. Age: ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. Locally advanced or solid tumors confirmed by histopathology and/or cytology that have failed or are intolerant to standard treatment, or for which no standard treatment currently exists;
  6. Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 3 years or fresh tissue samples;
  7. Must have at least one as defined by v1.1;
  8. (ECOG) performance status score of 0 or 1;
  9. Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by v5.0;
  10. No severe cardiac dysfunction, with ≥50%;
  11. Organ function levels must meet the requirements under the premise that no blood transfusion and no use of any cell growth factors and/or -elevating agents are allowed within 14 days before screening assessments;
  12. Coagulation function: (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 ;
  13. Urine protein ≤2+ or ≤1000 mg/24 h;
  14. For premenopausal women of , a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be breastfeeding; all enrolled patients (whether male or female) must use adequate barrier measures throughout the entire treatment period and for 6 months after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Prior antitumor therapy such as chemotherapy, biotherapy, or immunotherapy within 4 weeks or 5 half-lives before the first dose; mitomycin and nitrosoureas within 6 weeks before the first dose; oral fluorouracil drugs or palliative radiotherapy within 2 weeks before the first dose; Chinese patent medicines within 2 weeks before the first dose;
  2. History of severe cardiovascular or cerebrovascular disease;
  3. prolongation, complete left bundle branch block, grade III atrioventricular block, frequent and uncontrollable arrhythmias;
  4. Active disease and inflammatory disease;
  5. Diagnosis of other within 5 years before the first dose;
  6. Hypertension inadequately controlled with two antihypertensive drugs;
  7. History of ILD, or current radiation pneumonitis, or suspected such disease;
  8. Pulmonary disease defined as grade ≥2 according to v5.0; concurrent pulmonary disease causing clinically severe respiratory impairment;
  9. Patients with poorly controlled blood glucose;
  10. Patients with active central nervous system ;
  11. Patients with massive serous cavity effusion, or serous cavity effusion with symptoms, or inadequately controlled serous cavity effusion;
  12. Imaging examination indicating that the tumor has invaded or encased major vessels in the chest, neck, pharynx, etc.;
  13. History of pulmonary embolism or thrombotic events requiring therapeutic intervention within 6 months before screening; infusion device-related thrombosis excluded;
  14. History of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any of BL-M05D1;
  15. Prior organ transplantation or hematopoietic stem cell transplantation (Allo-HSCT);
  16. Cumulative anthracycline dose >360 mg/m2 in prior (neo) anthracycline therapy;
  17. Positive antibody, active tuberculosis, active virus infection, or active virus infection;
  18. Active infection requiring systemic treatment;
  19. Participation in another clinical trial within 4 weeks before the first dose;
  20. Pregnant or breastfeeding women;
  21. Esophageal or gastric varices requiring intervention within the past three months or diseases with a high risk of bleeding;
  22. History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection, etc.;
  23. Other circumstances in which the investigator considers the patient unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    BL-M05D1

    Participants receive BL-M05D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: BL-M05D1

Interventions

  • Administration by intravenous infusion for a cycle of 3 weeks.

06

What researchers measure

Primary outcomes

  1. Phase Ia: Dose limiting toxicity (DLT)

    DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.

    Time frame: Up to 21 days after the first dose

  2. Phase Ia: Maximum tolerated dose (MTD)

    MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle .

    Time frame: Up to 21 days after the first dose

  3. Phase Ib: Recommended Phase II Dose (RP2D)

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M05D1.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Treatment-Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M05D1 . The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M05D1.

    Time frame: Up to approximately 24 months

  2. Cmax

    Maximum serum concentration (Cmax) of BL-M05D1 will be investigated.

    Time frame: Up to approximately 24 months

  3. Tmax

    Time to maximum serum concentration (Tmax) of BL-M05D1 will be investigated.

    Time frame: Up to approximately 24 months

  4. T1/2

    Half-life (T1/2) of BL-M05D1 will be investigated.

    Time frame: Up to approximately 24 months

  5. AUC0-t

    AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.

    Time frame: Up to approximately 24 months

  6. CL (Clearance)

    CL in the serum of BL-M05D1 per unit of time will be investigated.

    Time frame: Up to approximately 24 months

  7. Ctrough

    Ctrough is defined as the lowest serum concentration of BL-M05D1 prior to the next dose will be administered.

    Time frame: Up to approximately 24 months

  8. ADA (anti-drug antibody)

    Frequency of anti-BL-M05D1 antibody (ADA) will be investigated.

    Time frame: Up to approximately 24 months

  9. Phase Ib: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.

    Time frame: Up to approximately 24 months

  10. Phase Ib: Disease Control Rate (DCR)

    The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]).

    Time frame: Up to approximately 24 months

  11. Phase Ib: Duration of Response (DOR)

    The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.

    Time frame: Up to approximately 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion May 2026 → Jun 2027 and completion May 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 5, 2024
StartActual
Apr 19, 2024
Primary completionEst.
Jun 2027was May 2026
CompletionEst.
Jun 2027was May 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Beijing Cancer Hospital · Beijing, China
Show 1 removed
  • Beijing Cancer Hospital · Beijing, China
Nov 2, 2026
Primary completion
May 2026→Jun 2027
Nov 2, 2026
Study completion
May 2026→Jun 2027
Nov 2, 2026
Eligibility
13 inclusion criteria edited; 17 exclusion criteria edited, 4 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedSignVoluntarily sign the informed consent form voluntarily and follow thecomply with protocol requirements;
  • ChangedBefore Gender is not limited;Now No gender restriction;
  • EditedAge: ≥18 years old and ≤75 years old;
  • EditedlocallyLocally advanced or metastatic solid tumors confirmed by histopathology and/or cytology with failurethat have failed or intoleranceare intolerant to standard treatment, or for which no standard treatment at presentcurrently exists;
  • ChangedBefore Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 3 years;Now Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 3 years or fresh tissue samples;
  • EditedAtMust have at least one measurable lesion meeting theas defined by RECIST v1.1 definition was required;
  • EditedEastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
  • EditedThe toxicity of previous antineoplasticToxicity from prior antitumor therapy has returnedrecovered to ≤ gradeGrade 1 as defined by NCI-CTCAE v5.0;
  • EditedNo severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;
  • EditedNoOrgan function levels must meet the requirements under the premise that no blood transfusion, and no use of any cell growth factors and/or platelet-raising drugselevating agents are allowed within 14 days before screening, and the organ function level must meet the requirements assessments;
  • EditedCoagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN5 ULN;
  • EditedUrinaryUrine protein ≤2+ or ≤1000mg1000 mg/24h24 h;
  • EditedFor premenopausal women withof childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactatingbreastfeeding; Allall enrolled patients (whether male or female) were advised tomust use adequate barrier contraceptioncontraceptive measures throughout the entire treatment cycleperiod and for 6 months after the end of treatment.
Exclusion criteria
  • EditedChemotherapyPrior antitumor therapy such as chemotherapy, biological therapybiotherapy, or immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycinmitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oraloral fluorouracil drugs or palliative radiotherapy within 2 weeks before the first dose; Chinese patent medicinemedicines within 2 weeks before the first administrationdose;
  • EditedHistory of severe cardiovascular andor cerebrovascular diseasesdisease;
  • EditedProlonged QT interval prolongation, complete left bundle branch block, grade III degree atrioventricular block, frequent and uncontrollable arrhythmiaarrhythmias;
  • EditedactiveActive autoimmune disease and inflammatory diseasesdisease;
  • EditedDiagnosis of other malignant tumors diagnosedmalignancies within 5 years before the first dose;
  • EditedHypertension poorlyinadequately controlled bywith two antihypertensive drugs;
  • ChangedBefore had a history of ILD or a suspicion of such disease on imaging during screening; The patient was diagnosed with grade ≥1 radiation pneumonitis according to the RTOG/EORTC definition;Now History of ILD, or current radiation pneumonitis, or suspected such disease;
  • EditedPulmonary disease defined as grade ≥2 according to CTCAE v5.0; Pulmonary diseases lead toconcurrent pulmonary disease causing clinically severe respiratory function impairment;
  • Removedpatients with poor glycemic control;
  • EditedPatients with massive or symptomatic effusions, or poorly controlled effusionsblood glucose;
  • AddedPatients with massive serous cavity effusion, or serous cavity effusion with symptoms, or inadequately controlled serous cavity effusion;
  • EditedImaging examination showedindicating that the tumor hadhas invaded or wrapped aroundencased major vessels in the chest, neck, pharynx and other large blood vessels, etc.;
  • Editedhad a historyHistory of pulmonary embolism or a thrombotic eventevents requiring therapeutic intervention within 6 months before screening; Infusioninfusion device-related thrombosis was excluded;
  • Editedhad a historyHistory of allergy to recombinant humanized antibodyantibodies or human-mouse chimeric antibodyantibodies, or allergy to any excipient of BL-M05D1 ingredients;
  • EditedThe cumulativeCumulative anthracycline dose of anthracyclines > 360 mg/m2 in previousprior (newneo) adjuvantadjuvant anthracycline therapy;
  • EditedPositive human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  • EditedactiveActive infection requiring systemic therapytreatment;
  • Editedhad participatedParticipation in another clinical trial within 4 weeks before the first dose;
  • EditedpregnantPregnant or lactatingbreastfeeding women;
  • RemovedThe investigator did not consider it appropriate to apply other criteria for participation in the trial.
  • AddedEsophageal or gastric varices requiring intervention within the past three months or diseases with a high risk of bleeding;
  • AddedHistory of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection, etc.;
  • AddedOther circumstances in which the investigator considers the patient unsuitable for participation in this clinical trial.
Nov 2, 2026
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.→Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • Beijing Cancer Hospital · Beijing, China
    Show 1 removed
    • Beijing Cancer Hospital · Beijing, China
    Primary completion May 2026→Jun 2027
    Study completion May 2026→Jun 2027
    Eligibility 13 inclusion criteria edited; 17 exclusion criteria edited, 4 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedSignVoluntarily sign the informed consent form voluntarily and follow thecomply with protocol requirements;
    • ChangedBefore Gender is not limited;Now No gender restriction;
    • EditedAge: ≥18 years old and ≤75 years old;
    • EditedlocallyLocally advanced or metastatic solid tumors confirmed by histopathology and/or cytology with failurethat have failed or intoleranceare intolerant to standard treatment, or for which no standard treatment at presentcurrently exists;
    • ChangedBefore Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 3 years;Now Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 3 years or fresh tissue samples;
    • EditedAtMust have at least one measurable lesion meeting theas defined by RECIST v1.1 definition was required;
    • EditedEastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
    • EditedThe toxicity of previous antineoplasticToxicity from prior antitumor therapy has returnedrecovered to ≤ gradeGrade 1 as defined by NCI-CTCAE v5.0;
    • EditedNo severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;
    • EditedNoOrgan function levels must meet the requirements under the premise that no blood transfusion, and no use of any cell growth factors and/or platelet-raising drugselevating agents are allowed within 14 days before screening, and the organ function level must meet the requirements assessments;
    • EditedCoagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN5 ULN;
    • EditedUrinaryUrine protein ≤2+ or ≤1000mg1000 mg/24h24 h;
    • EditedFor premenopausal women withof childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactatingbreastfeeding; Allall enrolled patients (whether male or female) were advised tomust use adequate barrier contraceptioncontraceptive measures throughout the entire treatment cycleperiod and for 6 months after the end of treatment.
    Exclusion criteria
    • EditedChemotherapyPrior antitumor therapy such as chemotherapy, biological therapybiotherapy, or immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycinmitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oraloral fluorouracil drugs or palliative radiotherapy within 2 weeks before the first dose; Chinese patent medicinemedicines within 2 weeks before the first administrationdose;
    • EditedHistory of severe cardiovascular andor cerebrovascular diseasesdisease;
    • EditedProlonged QT interval prolongation, complete left bundle branch block, grade III degree atrioventricular block, frequent and uncontrollable arrhythmiaarrhythmias;
    • EditedactiveActive autoimmune disease and inflammatory diseasesdisease;
    • EditedDiagnosis of other malignant tumors diagnosedmalignancies within 5 years before the first dose;
    • EditedHypertension poorlyinadequately controlled bywith two antihypertensive drugs;
    • ChangedBefore had a history of ILD or a suspicion of such disease on imaging during screening; The patient was diagnosed with grade ≥1 radiation pneumonitis according to the RTOG/EORTC definition;Now History of ILD, or current radiation pneumonitis, or suspected such disease;
    • EditedPulmonary disease defined as grade ≥2 according to CTCAE v5.0; Pulmonary diseases lead toconcurrent pulmonary disease causing clinically severe respiratory function impairment;
    • Removedpatients with poor glycemic control;
    • EditedPatients with massive or symptomatic effusions, or poorly controlled effusionsblood glucose;
    • AddedPatients with massive serous cavity effusion, or serous cavity effusion with symptoms, or inadequately controlled serous cavity effusion;
    • EditedImaging examination showedindicating that the tumor hadhas invaded or wrapped aroundencased major vessels in the chest, neck, pharynx and other large blood vessels, etc.;
    • Editedhad a historyHistory of pulmonary embolism or a thrombotic eventevents requiring therapeutic intervention within 6 months before screening; Infusioninfusion device-related thrombosis was excluded;
    • Editedhad a historyHistory of allergy to recombinant humanized antibodyantibodies or human-mouse chimeric antibodyantibodies, or allergy to any excipient of BL-M05D1 ingredients;
    • EditedThe cumulativeCumulative anthracycline dose of anthracyclines > 360 mg/m2 in previousprior (newneo) adjuvantadjuvant anthracycline therapy;
    • EditedPositive human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
    • EditedactiveActive infection requiring systemic therapytreatment;
    • Editedhad participatedParticipation in another clinical trial within 4 weeks before the first dose;
    • EditedpregnantPregnant or lactatingbreastfeeding women;
    • RemovedThe investigator did not consider it appropriate to apply other criteria for participation in the trial.
    • AddedEsophageal or gastric varices requiring intervention within the past three months or diseases with a high risk of bleeding;
    • AddedHistory of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection, etc.;
    • AddedOther circumstances in which the investigator considers the patient unsuitable for participation in this clinical trial.
    Sponsor Sichuan Baili Pharmaceutical Co., Ltd.→Biokin (Shanghai) Biopharmaceutical Co., Ltd.
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06349811
Lead sponsor
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
Apr 19, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
+8615013238943
Lin Shen, PHD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1

Start the discussion